Continuous glucose monitoring

Continuous glucose monitoring has been studied in 86 papers since 2017: 8 trials and 33 observational studies in people, 42 reviews; 65 in the past year. The newest story, Nov 4, 2026: “Average glucose linked to metabolic risk in adults without diabetes”.

Intervention

86 papers study it52 findingsUpdated

MeSH

15 new papers in 30 daysSee all 84 papers on continuous glucose monitoring

At a glance

Continuous glucose monitoring is linked with lower mortality across independent human cohorts, including insulin-treated older adults with ADRD and diabetes, but not clearly in well-controlled type 2 diabetes. A human trial reports lower HbA1c in older adults using multiple daily insulin injections, a change independently replicated. Papers include Dexcom-affiliated authors and declare ties to Dexcom, Abbott and other companies.

52 findings in 25 papers from 2017 to 2026, 10 of them since June 2026

Independent labs found the same change in people. 16 independent labs in 10 countries.

“Each day of sensor wear increased TITR by 0.59% (95% confidence interval [CI]: 0.50, 0.69, P < 0.001)”
Continuous Glucose Monitoring-Derived Glucose Metrics Over Time in Physically Active Adults Without Diabetes Using a Commercial Continuous Glucose Monitoring ApplicationJournal of diabetes science and technology2026doi:10.1177/19322968261426376

4 of its findings point the other way.

Humans: replicated by independent labs. Cells, worms or flies and mice: nothing yet.
  • 16 independent labs in 10 countries
  • 4 findings against
  • Funders: Korean Diabetes Association and others
  • 14 of 43 findings with company ties
  • Human trial8
  • Humans32

Studies in people

3 studies gave continuous glucose monitoring to people and measured what changed.

What changedDesignPeopleSource

down: Decreases body weight-2.7 ± 1.1 kg vs +0.5 ± 0.8 kg

down: Decreases energy intake-235.0 ± 123.0 kcal.day−1 vs +23.3 ± 201.6 kcal.day−1

no change: Has no effect on physical activity

Randomized trial24 weeks49 peopleBothGeneral populationClinical nutrition (Edinburgh, Scotland), Jul 21, 2026

up: Increases time in tight range0.59% per day (95% CI: 0.50, 0.69)

Trialapproximately eight weeks225 peopleBoth45.0 ± 10.1 yearsMidlife adults; mild dysglycemia at baseline (>5% time with glucose levels outside of 70-140 mg/dL)Journal of diabetes science and technology, Mar 3, 2026

down: Decreases HbA1cadjusted difference in mean change -0.4 ± 0.1%; -0.9% vs -0.5% from baseline

Randomized trial24 weeks116 people60 years and olderOlder adults; Patient cohortsJournal of diabetes science and technology, Apr 28, 2017

What did studies of continuous glucose monitoring find?

24

Studies of continuous glucose monitoring measured 24 outcomes; the most studied are glycemic control (3 studies), body weight (2) and HbA1c (2).

Glycemic control

upin humans3

3 studies
  1. Continuous glucose monitoring improves glycemic control in individuals with diabetes.

    Reviewin individuals with diabetes

  2. Continuous glucose monitoring improves glycemic control in humans (prediabetes).

    Reviewprediabetes

  3. Continuous glucose monitoring improves glycemic control in humans (noninsulin treated type 2 diabetes).

    Reviewnoninsulin treated type 2 diabetes

Body weight

no changein humans1downin humans1

2 studies
  1. Continuous glucose monitoring showed no clear effect on body weight in humans (Type 2 diabetes; compared with self-monitoring of blood glucose or usual care) (MD -0.67 kg, 95% CI -3.30 to 1.97).

    ReviewType 2 diabetes; compared with self-monitoring of blood glucose or usual care≥12 weeksn = 890

  2. Continuous glucose monitoring decreases body weight in humans (Type 2 diabetes, prediabetes, or overweight/obesity; versus control) (Mean difference −1.21 kg; 95% CI −1.88 to −0.54; p=0.0004).

    ReviewType 2 diabetes, prediabetes, or overweight/obesity; versus control

HbA1c

downin humans2

2 studies
  1. Continuous glucose monitoring decreases HbA1c in humans (adjusted difference in mean change -0.4 ± 0.1%; -0.9% vs -0.5% from baseline).

    Human trialcompared with self-monitoring blood glucose in older adults using multiple daily insulin injectionsDexcomTM G4 Platinum CGM System24 weeksn = 116

  2. Continuous glucose monitoring decreases HbA1c in humans (Type 2 diabetes; compared with self-monitoring of blood glucose or usual care) (MD -0.42%, 95% CI -0.51 to -0.33).

    ReviewType 2 diabetes; compared with self-monitoring of blood glucose or usual care≥12 weeksn = 2,252

More on HbA1c

Systolic blood pressure

no changein humans1

1 study
  1. Continuous glucose monitoring showed no clear effect on systolic blood pressure in humans (Type 2 diabetes; compared with self-monitoring of blood glucose or usual care) (MD +2.39 mmHg, 95% CI -2.03 to 6.82).

    ReviewType 2 diabetes; compared with self-monitoring of blood glucose or usual care≥12 weeksn = 521

Health behavior

upin humans1

1 study
  1. Continuous glucose monitoring improves health behavior in humans (Select studies in adults with or at risk for type 2 diabetes).

    ReviewSelect studies in adults with or at risk for type 2 diabetes

Maternal glycemic control

upin humans1

1 study
  1. Continuous glucose monitoring improves maternal glycemic control in pregnancy.

    Reviewin pregnancy

More on Maternal glycemic control

Physical activity

no changein humans1

1 study
  1. Continuous glucose monitoring showed no clear effect on physical activity in humans (combined with personalized dietitian-led weight loss maintenance program).

    Human trialcombined with personalized dietitian-led weight loss maintenance program24 weeks

Energy intake

downin humans1

1 study
  1. Continuous glucose monitoring decreases energy intake in humans (combined with personalized dietitian-led weight loss maintenance program) (-235.0 ± 123.0 kcal.day−1 vs +23.3 ± 201.6 kcal.day−1).

    Human trialcombined with personalized dietitian-led weight loss maintenance program24 weeks

Body weight

downin humans1

1 study
  1. Continuous glucose monitoring decreases body weight in humans (combined with personalized dietitian-led weight loss maintenance program) (-2.7 ± 1.1 kg vs +0.5 ± 0.8 kg).

    Human trialcombined with personalized dietitian-led weight loss maintenance program24 weeks

More on Body weight

A1C

downin humans1−0.4% greater reduction

1 study
  1. Continuous glucose monitoring is linked with lower A1C in humans (compared with non-CGM users) (0.4% greater reduction).

    Humanscompared with non-CGM users

More on A1C

Time in tight range

upin humans1

1 study
  1. Continuous glucose monitoring increases time in tight range in humans (mild dysglycemia at baseline (>5% time with glucose levels outside of 70-140 mg/dL)) (0.59% per day (95% CI: 0.50, 0.69)).

    Human trialmild dysglycemia at baseline (>5% time with glucose levels outside of 70-140 mg/dL)approximately eight weeksn = 225

More on Time in tight range

All 24

What is continuous glucose monitoring linked with?

18

Studies link continuous glucose monitoring with 18 measures, most often mortality (6 studies) and hyperglycemia (2).

Mortality

downin humans6HR 0.57–0.82

6 studies
  1. Continuous glucose monitoring is linked with a lower risk of mortality in humans (type 1 diabetes) (adjusted risk ratios of 0.90 (95% CI 0.71-0.97) to 0.84 (95% CI 0.72-0.97)).

    Humanstype 1 diabetes1-4 yearsn = 8,423

  2. Continuous glucose monitoring is linked with a lower risk of mortality in humans (type 1 diabetes receiving intensive insulin therapy) (aHR 0.38, 95% CI 0.32, 0.46).

    Humanstype 1 diabetes receiving intensive insulin therapy

  3. Continuous glucose monitoring is linked with a lower risk of mortality in insulin-treated older adults with ADRD and diabetes (HR 0.57, 95% CI 0.48-0.67).

    Humansin insulin-treated older adults with ADRD and diabetesn = 2,022

  4. Continuous glucose monitoring is linked with a lower risk of mortality in insulin-using older adults with diabetes and cognitive impairment/ADRD (HR 0.57 (95% CI 0.48-0.67)).

    Humansin insulin-using older adults with diabetes and cognitive impairment/ADRD

  5. Continuous glucose monitoring is linked with a lower risk of mortality in humans (type 2 diabetes on any insulin therapy) (HR 0.82, 95% CI 0.71-0.94, p=0.004).

    Humanstype 2 diabetes on any insulin therapy5 yearsn = 27,576

  6. Continuous glucose monitoring is linked with a lower risk of mortality in humans (type 2 diabetes receiving insulin) (HR 0.79 (95% CI 0.73-0.86)).

    Humanstype 2 diabetes receiving insulin18 monthsmale (94%)s

Hyperglycemia

upin humans1downin humans1HR 0.88–1.78

2 studies
  1. Continuous glucose monitoring is linked with a higher risk of hyperglycemia in older adults with type 1 diabetes and cognitive impairment/ADRD (HR 1.78 (95% CI 1.15-2.75)).

    Humansin older adults with type 1 diabetes and cognitive impairment/ADRD

  2. Continuous glucose monitoring is linked with a lower risk of hyperglycemia in humans (type 2 diabetes receiving insulin) (HR 0.88 (95% CI 0.81-0.95)).

    Humanstype 2 diabetes receiving insulin18 monthsmale (94%)s

More on Hyperglycemia

Prediabetes diagnostic discrimination

mixedin humans1

1 study
  1. Continuous glucose monitoring predicts prediabetes diagnostic discrimination in humans (Threshold of 5.64% time above 140 mg/dL) (88% specificity and 48% sensitivity).

    ReviewThreshold of 5.64% time above 140 mg/dL

HbA1c

downin humans1

1 study
  1. Continuous glucose monitoring is associated with HbA1c in humans (type 2 diabetes mellitus; single-arm pre-post comparison) (HbA1c decreased from 8.12% to 7.49%).

    Humanstype 2 diabetes mellitus; single-arm pre-post comparisonintermittently scanned12 weeksn = 542

More on HbA1c

Gestational diabetes mellitus

upin humans1

1 study
  1. Continuous glucose monitoring predicts gestational diabetes mellitus in humans (dynamic model combining V1 and V2 CGM metrics with clinical predictors) (AUC 0.84).

    Humansdynamic model combining V1 and V2 CGM metrics with clinical predictorsfemalesn = 1,539

More on Gestational diabetes mellitus

All-cause death

downin humans1HR 0.77

1 study
  1. Continuous glucose monitoring is linked with a lower risk of all-cause death in humans after propensity score matching (HR 0.77, 95% CI 0.73–0.81).

    Humansafter propensity score matchingmedian follow-up of 2.1 years

Cardiovascular-related death

downin humans1HR 0.77

1 study
  1. Continuous glucose monitoring is linked with a lower risk of cardiovascular-related death in humans after propensity score matching (HR 0.77, 95% CI 0.72–0.83).

    Humansafter propensity score matchingmedian follow-up of 2.1 years

Stroke

downin humans1HR 0.95

1 study
  1. Continuous glucose monitoring is linked with a lower risk of stroke in humans after propensity score matching (HR 0.95, 95% CI 0.93–0.98).

    Humansafter propensity score matchingmedian follow-up of 2.1 years

More on Stroke

Myocardial infarction

downin humans1HR 0.95

1 study
  1. Continuous glucose monitoring is linked with a lower risk of myocardial infarction in humans after propensity score matching (HR 0.95, 95% CI 0.92–0.99).

    Humansafter propensity score matchingmedian follow-up of 2.1 years

More on Myocardial infarction

Cardiovascular disease

downin humans1

1 study
  1. Continuous glucose monitoring is linked with a lower risk of cardiovascular disease in humans (type 1 diabetes receiving intensive insulin therapy) (aHR 0.28, 95% CI 0.23, 0.33).

    Humanstype 1 diabetes receiving intensive insulin therapy

More on Cardiovascular disease

All 18

Funding

10 grants since 2021

National Institute of Diabetes and Digestive and Kidney Diseases$2.1MJapan Society for the Promotion of Science¥11.2MInnovative UK£775K

Contains public sector information licensed under the Open Government Licence v3.0.

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 2Jan 2026: 9Feb 2026: 6Mar 2026: 6Apr 2026: 0May 2026: 1Jun 2026: 10Jul 2026: 2Aug 2026: 3Sep 2026: 5Oct 2026: 8Nov 2026: 961 papers in 12 months
medRxiv

Average glucose linked to metabolic risk in adults without diabetes

Average glucose explained nearly three times more variation in fasting insulin, a hormone that controls blood sugar, than a standard blood sugar test.Average glucose explained nearly three times more variation in fasting insulin, a hormone that controls blood sugar, than a standard blood sugar test.

Preprint: cross-sectional · 7,930 peopleBiomarkers

See all 84 papers on continuous glucose monitoring